• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

Pre-term deliveries due to COVID-19 could be avoided by studying EHRs

Bioengineer by Bioengineer
June 10, 2020
in Immunology
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Anup Challa

Using electronic health record (EHR) data to simulate drug trials for pregnant patients could one day offer a solution to the current practice of delivering babies pre-term if an expectant mother contracts COVID-19, according to a position paper published in Nature Medicine.

Pregnant patients have typically been excluded from drug trials out of concern for fetal safety. And when human health is on the line, drug studies assessing fetal safety in animal models may be viewed as far from definitive. Due to sheer lack of data concerning implications for fetal and maternal safety, clinicians are often unsure about prescribing drugs to pregnant patients.

A position paper led by first author Anup Challa and senior author David Aronoff, MD, director, Division of Infectious Diseases at Vanderbilt University Medical Center (VUMC), outlines how these deficits can lead to undertreatment of chronic and acute illness in pregnant patients, while also posing additional risk of adverse drug reactions.

“Pregnant patients are an especially vulnerable population, since exposure to many common drugs could harm their unborn children,” said Challa, principal investigator of Modeling Adverse Drug Reactions in Embryos (MADRE), a team of drug safety researchers across Vanderbilt, Northwestern, Harvard, and the National Institutes of Health. “Further complicating this problem is the fact that pregnant patients are not allowed to enroll in clinical trials, given the ethical issues that a harmful drug reaction in their fetuses could pose.

“These factors have significantly reduced quality of care for pregnant patients with COVID-19, as the current guidance to OB/GYNs is to deliver pregnant patients if they contract COVID-19, even if the patients are pre-term. This could significantly harm their fetuses, and recent case reports have shown that COVID-19 transmission occurs in utero if not treated in the mother,” he added.

Challa and Aronoff propose that using EHR data to emulate randomized, controlled trials could offer an alternative to delivering all pregnant patients with COVID-19.

Used to compare treatments, these trials involve enrollment of subjects who undergo interventions carried out in real time. In contrast, target trials are a type of observational study that simulates the trial through retrospective analysis of existing clinical data.

“We could identify therapeutics that are safe for use in these patients by using high-powered algorithms like machine learning to learn from cases in which pregnant patients have been exposed to current therapeutic candidates and understand how much risk they pose to a fetus,” Aronoff said.

VUMC has EHRs for more than 2 million patients, which allows investigators to design and conduct “trials” that simulate not only a real trial’s treatment strategies (drug vs. no drug) and outcomes, but also eligibility criteria and random assignment to treatment at baseline.

Such trials are arguably “the only ethical way to gather human drug exposure data for pregnant people on a significant scale and across all classes of drugs,” the authors said.

“If expanded, the Vanderbilt platform of target trials may offer an alternative to delivering all pregnant patients with COVID-19 by identifying therapeutics that are safe,” Challa said. “Without a good understanding of safety for these drugs, we might be missing opportunities to treat COVID-19 in pregnant patients.”

###

In addition to Challa and Aronoff, co-authors include Robert Lavieri, PhD, Ethan Lippmann, PhD, Lisa Bastarache, MS, Jill Pulley, MBA, and Jeffery Goldstein, MD, PhD.

Media Contact
Craig Boerner
[email protected]

Related Journal Article

http://dx.doi.org/10.1038/s41591-020-0925-1

Tags: Clinical TrialsFertilityInfectious/Emerging DiseasesMedical/Scientific EthicsMedicine/HealthPediatrics
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

UMass Amherst grad student awarded fellowship for food allergy research

July 23, 2021
IMAGE

Less-sensitive COVID-19 tests may still achieve optimal results if enough people tested

July 22, 2021

Public trust in CDC, FDA, and Fauci holds steady, survey shows

July 20, 2021

USC study shows male-female differences in immune cell function

July 19, 2021
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    92 shares
    Share 37 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    82 shares
    Share 33 Tweet 21
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Movement Skills Boost Executive Function in Autistic Kids

Mayo Clinic Secures Up to $40 Million from ARPA-H to Advance Groundbreaking Air Safety Research

Atlas Reveals Testicular Aging Across Species

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.